IP Library › Granted Patent US 10,702,600
Granted Patent B1
US 10,702,600 · App. 16/805,587 · Granted Jul 7, 2020

Betacoronavirus mRNA vaccine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,702,600
App. No.
16/805,587
Granted
Jul 7, 2020
Kind
B1
Abstract

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Claims (26)

1. A composition, comprising: a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.

2. The composition of claim 1 , wherein the open reading frame encodes a BetaCoV S protein.

3. The composition of claim 1 , wherein the open reading frame encodes an S protein subunit selected from an S1 subunit and an S2 subunit.

4. The composition of claim 1 , wherein the mRNA further comprising a 5′ untranslated region (UTR) and a 3′ UTR.

5. The composition of claim 4 , wherein the mRNA further comprises a poly(A) tail.

6. The composition of claim 4 , wherein the mRNA further comprises a 5′ cap analog.

7. The composition of claim 6 , wherein the 5′ cap analog is 7mG(5′)ppp(5′)NlmpNp.

8. The composition of claim 1 , wherein the mRNA comprises a chemical modification.

9. The composition of claim 8 , wherein the chemical modification is a 1-methylpseudouridine modification or a 1-ethylpseudouridine modification.

10. The composition of claim 8 , wherein at least 80% of the uracil in the open reading frame has a chemical modification.

11. The composition of claim 1 , wherein the lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.

12. The composition of claim 11 , wherein the lipid nanoparticle comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% cholesterol, and 0.5-15% PEG-modified lipid.

13. The composition of claim 12 , wherein the lipid nanoparticle comprises 50% ionizable cationic lipid, 10% neutral lipid, 38.5% sterol, and 1.5% PEG-modified lipid.

14. The composition of claim 11 , wherein the ionizable cationic lipid is Compound 25.

15. The composition of claim 11 , wherein the neutral lipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the sterol is cholesterol, and the PEG-modified lipid is 1,2-dimyristoyl-racalycero-3-methoxypolyethylene glycol-2000 (PEG-DMG) or PEG-cDMA.

16. A composition, comprising: a messenger ribonucleic acid (mRNA) comprising a 5′ untranslated region (UTR), an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit, a 3′ UTR, and a poly(A) tail, formulated in a lipid nanoparticle that comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% cholesterol, and 0.5-15% PEG-modified lipid.

17. The composition of claim 16 , wherein the open reading frame encodes a BetaCoV S protein.

18. The composition of claim 16 , wherein the open reading frame encodes an S protein subunit selected from an S1 subunit and an S2 subunit.

19. The composition of claim 16 , wherein the mRNA further comprises 5′ cap analog 7mG(5′)ppp(5′)NlmpNp.

20. The composition of claim 16 , wherein at least 80% of the uracil in the open reading frame has a chemical modification.

21. The composition of claim 20 , wherein the chemical modification is a 1-methylpseudouridine modification or a 1-ethylpseudouridine modification.

22. The composition of claim 16 , wherein the ionizable cationic lipid is Compound 25.

23. The composition of claim 16 , wherein the neutral lipid is DSPC, the sterol is cholesterol, and the PEG-modified lipid is PEG-DMG.

24. A composition, comprising: a messenger ribonucleic acid (mRNA) comprising a 5′ cap analog, a 5′ untranslated region (UTR), an open reading frame encoding a betacoronavirus (BetaCoV) S protein, a 3′ UTR, and a poly(A) tail, formulated in a lipid nanoparticle that comprises 20-60% ionizable cationic lipid, 5-25% DSPC, 25-55% cholesterol, and 0.5-15% PEG-DMG, wherein the ionizable cationic lipid has the structure of Compound 25, and wherein at least 80% of the uracil in the open reading frame has a 1-methylpseudouridine modification.

25. The composition of claim 24 , wherein the 5′ cap analog is 7mG(5′)ppp(5′)NlmpNp.

26. A lipid nanoparticle, comprising: a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit; wherein the lipid nanoparticle comprises 20-60% ionizable cationic lipid, 5-25% neutral lipid, 25-55% cholesterol, and 0.5-15% PEG-modified lipid.

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2020
From: CIARAMELLA, GIUSEPPE; HIMANSU, SUNNY
To: MODERNATX, INC.
Reel/Frame 052134/0690 →